187 related articles for article (PubMed ID: 32650019)
1. Interleukin 6 levels after tocilizumab administration in transplant recipients with COVID-19.
Gade AR; Alavala H; Allam SR
Kidney Int; 2020 Oct; 98(4):1054. PubMed ID: 32650019
[No Abstract] [Full Text] [Related]
2. Interleukin-6 receptor antagonist therapy to treat SARS-CoV-2 driven inflammatory syndrome in a kidney transplant recipient.
Allam SR; Dao A; Madhrira MM; Antiporta PB; Nair RR; Guiteau JJ; Reyad AI
Transpl Infect Dis; 2020 Aug; 22(4):e13326. PubMed ID: 32406985
[No Abstract] [Full Text] [Related]
3. Tocilizumab for Hemophagocytic Syndrome in a Kidney Transplant Recipient With COVID-19.
Faguer S; Del Bello A; Abravanel F; Nicolau-Travers ML; Kamar N
Ann Intern Med; 2020 Sep; 173(6):501-503. PubMed ID: 32432518
[No Abstract] [Full Text] [Related]
4. Kidney Transplantation and COVID-19.
Merhi B; Gohh R
R I Med J (2013); 2020 Sep; 103(8):34-37. PubMed ID: 32900010
[No Abstract] [Full Text] [Related]
5. Rapid resolution of cytokine release syndrome and favorable clinical course of severe COVID-19 in a kidney transplant recipient treated with tocilizumab.
Gautier-Vargas G; Baldacini C; Benotmane I; Keller N; Perrin P; Moulin B; Caillard S
Kidney Int; 2020 Aug; 98(2):508-509. PubMed ID: 32505467
[No Abstract] [Full Text] [Related]
6. Cytokine release syndrome in severe COVID-19.
Moore JB; June CH
Science; 2020 May; 368(6490):473-474. PubMed ID: 32303591
[No Abstract] [Full Text] [Related]
7. Interleukin 6-blockade treatment for severe COVID-19 in two patients with multiple myeloma.
Chaidos A; Katsarou A; Mustafa C; Milojkovic D; Karadimitris A
Br J Haematol; 2020 Jul; 190(1):e9-e11. PubMed ID: 32369612
[No Abstract] [Full Text] [Related]
8. Acute Hypertriglyceridaemia Caused by Tocilizumab in a Patient with Severe COVID-19.
Nakamura H; Miyagi K; Otsuki M; Higure Y; Nishiyama N; Kinjo T; Nakamatsu M; Haranaga S; Tateyama M; Fujita J
Intern Med; 2020 Nov; 59(22):2945-2949. PubMed ID: 32963155
[TBL] [Abstract][Full Text] [Related]
9. Lack of tocilizumab effect on mortality in COVID19 patients.
Holt GE; Batra M; Murthi M; Kambali S; Santos K; Bastidas MVP; Asif H; Haddadi S; Arias S; Mirsaeidi M
Sci Rep; 2020 Oct; 10(1):17100. PubMed ID: 33051534
[TBL] [Abstract][Full Text] [Related]
10. The Immunocompromised Transplant Recipient and SARS-CoV-2 Infection.
Fishman JA
J Am Soc Nephrol; 2020 Jun; 31(6):1147-1149. PubMed ID: 32345701
[No Abstract] [Full Text] [Related]
11. Interleukin-6 blockade treatment for COVID-19 associated cytokine release syndrome in a patient with poorly controlled chronic myeloid leukaemia.
Ranger A; Haji R; Kaczmarski R; Danga A
Br J Haematol; 2020 Aug; 190(3):e128-e130. PubMed ID: 32480422
[No Abstract] [Full Text] [Related]
12. Recovery of COVID-19 acute respiratory distress syndrome with tocilizumab: successful outcome in two critically ill patients.
Cala-García JD; Sierra-Bretón JD; Cavelier-Baiz JE; Faccini-Martínez ÁA; Pérez-Díaz CE
Immunotherapy; 2020 Oct; 12(15):1127-1132. PubMed ID: 32664810
[No Abstract] [Full Text] [Related]
13. Utilizing tocilizumab for the treatment of cytokine release syndrome in COVID-19.
Hassoun A; Thottacherry ED; Muklewicz J; Aziz QU; Edwards J
J Clin Virol; 2020 Jul; 128():104443. PubMed ID: 32425661
[No Abstract] [Full Text] [Related]
14. COVID-19 in Liver Transplant Recipients: An Initial Experience From the US Epicenter.
Lee BT; Perumalswami PV; Im GY; Florman S; Schiano TD;
Gastroenterology; 2020 Sep; 159(3):1176-1178.e2. PubMed ID: 32442561
[No Abstract] [Full Text] [Related]
15. Anti-IL6R role in treatment of COVID-19-related ARDS.
Buonaguro FM; Puzanov I; Ascierto PA
J Transl Med; 2020 Apr; 18(1):165. PubMed ID: 32290847
[No Abstract] [Full Text] [Related]
16. Tocilizumab for COVID-19: a real 'miracle drug'?
Nasim S; Hashmi SH; Azim D; Kumar S; Nasim J
Infect Dis (Lond); 2020 Sep; 52(9):681-682. PubMed ID: 32644027
[No Abstract] [Full Text] [Related]
17. Dramatic improvement after tocilizumab of severe COVID-19 in a child with sickle cell disease and acute chest syndrome.
Odièvre MH; de Marcellus C; Ducou Le Pointe H; Allali S; Romain AS; Youn J; Taytard J; Nathan N; Corvol H
Am J Hematol; 2020 Aug; 95(8):E192-E194. PubMed ID: 32358817
[No Abstract] [Full Text] [Related]
18. Oligosymptomatic Kidney Transplant Patients With COVID-19: Do They Pose a Risk to Other Recipients?
Kocak B; Arpali E; Akyollu B; Yelken B; Tekin S; Kanbay M; Turkmen A; Kalayoglu M
Transplant Proc; 2020 Nov; 52(9):2663-2666. PubMed ID: 32419709
[TBL] [Abstract][Full Text] [Related]
19. The Combined Use of Tocilizumab and Hemoadsorption in a Patient with SARS-COV-2-19-Associated Pneumonia: A Case Report.
Berlot G; Tomasini A; Roman Pognuz E; Randino A; Chiella F; La Fata C; Piva M; Amato P; di Maso V; Bianco F; Gerini U; Tomietto P; Trenti T
Nephron; 2020; 144(9):459-462. PubMed ID: 32694244
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of corticoid pulses in patients with cytokine storm syndrome induced by SARS-CoV-2 infection.
Callejas Rubio JL; Luna Del Castillo JD; de la Hera Fernández J; Guirao Arrabal E; Colmenero Ruiz M; Ortego Centeno N
Med Clin (Barc); 2020 Aug; 155(4):159-161. PubMed ID: 32532461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
